TY - JOUR
T1 - Large Scale Identification of Variant Proteins in Glioma Stem Cells
AU - Mostovenko, Ekaterina
AU - Végvári, Ákos
AU - Rezeli, Melinda
AU - Lichti, Cheryl F.
AU - Fenyö, David
AU - Wang, Qianghu
AU - Lang, Frederick F.
AU - Sulman, Erik P.
AU - Sahlin, K. Barbara
AU - Marko-Varga, György
AU - Nilsson, Carol L.
N1 - Publisher Copyright:
© 2017 American Chemical Society.
PY - 2018/1/17
Y1 - 2018/1/17
N2 - Glioblastoma (GBM), the most malignant of primary brain tumors, is a devastating and deadly disease, with a median survival of 14 months from diagnosis, despite standard regimens of radical brain tumor surgery, maximal safe radiation, and concomitant chemotherapy. GBM tumors nearly always re-emerge after initial treatment and frequently display resistance to current treatments. One theory that may explain GBM re-emergence is the existence of glioma stemlike cells (GSCs). We sought to identify variant protein features expressed in low passage GSCs derived from patient tumors. To this end, we developed a proteomic database that reflected variant and nonvariant sequences in the human proteome, and applied a novel retrograde proteomic workflow, to identify and validate the expression of 126 protein variants in 33 glioma stem cell strains. These newly identified proteins may harbor a subset of novel protein targets for future development of GBM therapy.
AB - Glioblastoma (GBM), the most malignant of primary brain tumors, is a devastating and deadly disease, with a median survival of 14 months from diagnosis, despite standard regimens of radical brain tumor surgery, maximal safe radiation, and concomitant chemotherapy. GBM tumors nearly always re-emerge after initial treatment and frequently display resistance to current treatments. One theory that may explain GBM re-emergence is the existence of glioma stemlike cells (GSCs). We sought to identify variant protein features expressed in low passage GSCs derived from patient tumors. To this end, we developed a proteomic database that reflected variant and nonvariant sequences in the human proteome, and applied a novel retrograde proteomic workflow, to identify and validate the expression of 126 protein variants in 33 glioma stem cell strains. These newly identified proteins may harbor a subset of novel protein targets for future development of GBM therapy.
KW - GBM
KW - Glioblastoma
KW - bioinformatics
KW - parallel reaction monitoring
KW - precision medicine
KW - protein quantification
KW - protein single amino acid variants
KW - proteomics
KW - targeted mass spectrometry
KW - transcriptomics
UR - https://www.scopus.com/pages/publications/85040656011
U2 - 10.1021/acschemneuro.7b00362
DO - 10.1021/acschemneuro.7b00362
M3 - Article
C2 - 29254333
AN - SCOPUS:85040656011
SN - 1948-7193
VL - 9
SP - 73
EP - 79
JO - ACS Chemical Neuroscience
JF - ACS Chemical Neuroscience
IS - 1
ER -